AbCellera Biologics (ABCL) Other Non-Current Liabilities (2020 - 2026)

AbCellera Biologics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $11.3 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 597.11% year-over-year to $11.3 million; the trailing twelve-month figure through Mar 2026 stood at $11.3 million (up 597.11% YoY), and the FY2025 full-year result was $13.9 million, up 93.65% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $11.3 million, down from $13.9 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $30.6 million in Q1 2022, with the low at $1.4 million in Q3 2025.
• Historically, Other Non-Current Liabilities has averaged $6.6 million across 5 years, with a median of $5.1 million in 2023.
• The largest YoY upside for Other Non-Current Liabilities was 3189.26% in 2022 against a maximum downside of 93.64% in 2022.
• AbCellera Biologics' Other Non-Current Liabilities stood at $3.1 million in 2022, then surged by 91.38% to $5.9 million in 2023, then rose by 21.39% to $7.2 million in 2024, then soared by 93.65% to $13.9 million in 2025, then retreated by 18.45% to $11.3 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $11.3 million (Q1 2026), $13.9 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.